Features | Partner Sites | Information | LinkXpress
Sign In

Whole Body, Diffusion-Weighted MRI Scan Could Optimize Bone Marrow Cancer Treatment

By Medimaging International staff writers
Posted on 06 Feb 2014
Image: ICR researchers pioneer scanning technique that can image a patient’s entire body to reveal where cancer is affecting the bones (Photo courtesy of ICR - Institute of Cancer Research).
Image: ICR researchers pioneer scanning technique that can image a patient’s entire body to reveal where cancer is affecting the bones (Photo courtesy of ICR - Institute of Cancer Research).
An innovative scanning technique that images a patient’s entire body can reveal where cancer is affecting the bones and guide physicians in the optimal choice of treatment.

The new type of magnetic resonance imaging (MRI) scan could enhance care for a type of cancer called myeloma and reduce reliance on bone marrow biopsies, which can be painful for patients and frequently cannot show clinicians how far the disease has metastasized.

The study’s findings were published January 28, 2014, in the journal Radiology. The new whole-body, diffusion-weighted MRI scans demonstrated the spread of cancer throughout the bone marrow of patients with myeloma, one of the most common forms of blood cancer, more effectively than conventional tests. The scans also showed whether the patients were responding to cancer treatments.

In the study, 26 patients had whole-body, diffusion-weighted MRI scanning before and after treatment. In 86% of patients, experienced doctors trained in imaging were able to correctly identify whether patients responded to treatment. In addition, they also accurately identified those patients who were not responding to treatment 80% of the time. Using the scanning technique, clinicians could target precisely where the cancer was in the bones, with the results available immediately. Conventional tests include bone marrow biopsies and blood tests; however, neither shows accurately where the cancer is present in the bones.

The researchers also evaluated the visible alterations on the MRI scans, using a measurement called the apparent diffusion coefficient (ADC), which records how restricted water movement is within tissues. Changes in this measurement correctly identified treatment response for 24 of 25 myeloma patients. The ADC is a quantitative measure of the random thermal movement of water protons within tissues. Water movement is more limited in tumors because their high cell density restricts the movement of extracellular water.

The new technology was able to image cancer in nearly all the bones in the body, with only the skull remaining difficult to image partly because of the frequency of metal dental implants and fillings. The researchers also discovered that the new imaging techniques were suitable for more patients than conventional tests; for instance, seven patients had bone marrow biopsies but their samples were found to be inadequate for analysis. Performing another biopsy could be traumatic and painful, and may not provide any new information.

Nandita deSouza, professor of translational imaging at the Institute of Cancer Research (ICR; London, UK) and honorary consultant at the Royal Marsden (London, UK), said, “This is the first time we’ve been able to obtain information from all the bones in the entire body for myeloma in one scan without having to rely on individual bone X-rays. It enables us to measure the involvement of individual bones and follow their response to treatment. The results can be visualized immediately; we can look on the screen and see straight away where the cancer is and measure how severe it is. The scan is better than blood tests, which don’t tell us in which bones the cancer is located. It also reduces the need for uncomfortable biopsies, which don’t reveal the extent or severity of the disease.”

Dr. Faith Davies, member of the myeloma targeted treatment team at the Institute of Cancer Research and consultant at the Royal Marsden, said, “Myeloma can affect bones anywhere in the body, which is why this study is so important. We’ve shown that whole body MRI scans can accurately monitor how myeloma patients are responding to treatment, allowing doctors to make more informed decisions. With this new scan, if a treatment isn’t working the patient can be moved onto new therapies that might be more effective much more quickly. This is a small study, so our next step will be to try out the technology in more patients and refine it. In the future, we hope this new tool will help doctors extend the life of more myeloma patients. ”

Julia Frater, Cancer Research UK’s (London) senior cancer information nurse, said, “Finding kinder ways to monitor how patients respond to treatment is really important, particularly in the case of myeloma where taking bone marrow samples can be painful. This research demonstrates how an advanced imaging technique could provide a whole-skeleton ‘snapshot’ to track the response of tumors in individual bones. Finding ways to make treatments gentler and improve the experience for patients is an important focus for Cancer Research UK and the research we fund.”

Related Links:

The Institute of Cancer Research

SuperSonic Imagine



view channel

Leading Cancer Center Among First in Europe to Treat Patients Using Robotic Patient-Positioning Radiotherapy Couch

A Viennese hospital has become one of the first oncology departments in Europe to introduce clinical treatments using a robotic radiotherapy patient-positioning couch. Kaiser-Franz-Josef Hospital (KFJ; Vienna, Austria) has introduced this enhanced patient positioning device, which enables more flexibility during radiotherapy... Read more


view channel
Image: Analogic Sonic Window handheld ultrasound for peripheral IV placement (Photo courtesy of Analogic).

First-of-a-Kind Ultrasound System Designed for Image-Guided Peripheral Intravenous Access and Fits in Pocket

A new, ultra-compact ultrasound device provides direct visualization of structures beneath the skin in real time to effectively guide clinicians placing peripheral intravenous (IV) lines.... Read more

Nuclear medicine

view channel
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.... Read more

General/Advanced Imaging

view channel

Secondary Light Emission Generated by Plasmonic Nanostructures May Improve Medical Imaging Technology

New clues into light emission at different wavelengths generated by elements known plasmonic nanostructures may help to improve medical imaging technology. A plasmon is a quantum of plasma oscillation. The plasmon is a quasiparticle resulting from the quantization of plasma oscillations just as photons, and phonons are... Read more

Imaging IT

view channel

Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography). Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
Copyright © 2000-2014 Globetech Media. All rights reserved.